XTalks

DECEMBER 13, 2024

XTALKS WEBINAR: Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data Live and On-Demand: Thursday, January 16, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

Antibody 99

Antibody In-Vivo Trials In-Vitro 99

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion.

In-Vivo 52

In-Vivo Marketing Engineer Genetics 52

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

MAY 22, 2023

“This unique product is a result of our vast experience in hyaluronic acid science and complements our current collection of hyaluronic acid products, with the Juvéderm collection of fillers and SkinMedica topicals.” “Skin quality is among the top concerns my patients express when seeking aesthetic treatments. .

Filler 92

Filler FDA Approval Dermatology In-Vivo 92

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

XTalks

APRIL 24, 2023

Rare diseases can often be progressive, chronic and fatal. Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Sadly, one-third of children with rare diseases die before their first birthday.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. A solution could be at hand with Overland Pharmaceuticals. Overland aims to build a leading, fully integrated biopharma company by leveraging global networks and formative R&D partnerships.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52